I-Mab Biopharma GAAP EPADS of -$0.04

Stock Information for I-MAB

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About I-MAB

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement
I-Mab to Participate in the H.C. Wainwright "HCW@Home" Series
I-Mab to Present at Jefferies Global Healthcare Conference
I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update
I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.